Platinum-based chemotherapy extended OS in BRCA-associated pancreatic ductal adenocarcinoma
Patients with advanced BRCA-associated pancreatic ductal adenocarcinoma treated with platinum-based chemotherapy experienced longer OS than those who received non-platinum therapy, according to study results.
BRCA1 and BRCA2 proteins have a role in regulation of cellular proliferation by DNA damage repair. Consequently, patients with pancreatic cancer who are carriers of BRCA1 and BRCA2 mutations may have distinct biologic outcomes, according to background information in the study.
Talia Golan, MD, of The Oncology Institute at the Chaim Sheba Medical Center in Israel, and colleagues pooled data on 71 patients diagnosed with BRCA1- and BRCA2-associated pancreatic ductal adenocarcinoma between January 1994 and December 2012.
Mean age at diagnosis was 60.3 years; 81.7% of patients had a family history of malignancy; and 30% underwent primary resection.
Twelve patients underwent experimental therapy and data was missing for one other patient, so those individuals were excluded from the OS analysis.
Median OS for the remaining 58 patients was 14 months (95% CI, 10-23).
At 60 months, 52% of patients with stage I or stage II disease were alive, and median OS for those patients had not been reached.
Median OS for patients with stage III or stage IV disease was 12 months (95% CI, 6-15). Among those with stage III or stage IV disease, median survival was 22 months among those who underwent platinum chemotherapies vs. 9 months for those treated with non-platinum chemotherapies (P=.039).
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.